IL326224A - Antibody conjugates and fusion proteins - Google Patents

Antibody conjugates and fusion proteins

Info

Publication number
IL326224A
IL326224A IL326224A IL32622426A IL326224A IL 326224 A IL326224 A IL 326224A IL 326224 A IL326224 A IL 326224A IL 32622426 A IL32622426 A IL 32622426A IL 326224 A IL326224 A IL 326224A
Authority
IL
Israel
Prior art keywords
fusion proteins
antibody conjugates
conjugates
antibody
fusion
Prior art date
Application number
IL326224A
Other languages
Hebrew (he)
Original Assignee
Sixpeaks Bio Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sixpeaks Bio Ag filed Critical Sixpeaks Bio Ag
Publication of IL326224A publication Critical patent/IL326224A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
IL326224A 2023-07-31 2024-07-31 Antibody conjugates and fusion proteins IL326224A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23188568 2023-07-31
PCT/EP2024/071630 WO2025027052A1 (en) 2023-07-31 2024-07-31 Antibody conjugates and fusion proteins

Publications (1)

Publication Number Publication Date
IL326224A true IL326224A (en) 2026-03-01

Family

ID=87554544

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326224A IL326224A (en) 2023-07-31 2024-07-31 Antibody conjugates and fusion proteins

Country Status (3)

Country Link
AU (1) AU2024317572A1 (en)
IL (1) IL326224A (en)
WO (1) WO2025027052A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026037938A1 (en) * 2024-08-16 2026-02-19 Protuoso Pte. Ltd. Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
JP5766179B2 (en) 2009-04-27 2015-08-19 ノバルティス アーゲー Compositions and methods for increasing muscle growth
HUE040276T2 (en) * 2011-07-01 2019-02-28 Novartis Ag Method for treating metabolic disorders
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
JP2015525230A (en) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド Dual receptor antagonistic antigen binding protein and uses thereof
WO2014172448A2 (en) 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
LT3129406T (en) 2014-04-11 2019-04-10 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
JP6987072B2 (en) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド Activin type 2 receptor binding protein and its use
JOP20190152A1 (en) 2016-12-21 2019-06-20 Novartis Ag Myostatin, activin or activin receptor antagonists for use in the treatment of obesity and related conditions
AU2020284038A1 (en) 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof
US20230220085A1 (en) 2020-02-28 2023-07-13 The Brigham And Women’S Hospital, Inc. Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
MX2023014840A (en) * 2021-06-23 2024-02-12 Scholar Rock Inc A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders.
JP2024532619A (en) 2021-08-27 2024-09-05 バーサニス バイオ、インコーポレイテッド Combination therapy
TW202339798A (en) * 2022-01-19 2023-10-16 美商維紗妮絲生物公司 Actrii antibody treatments

Also Published As

Publication number Publication date
AU2024317572A1 (en) 2026-03-12
WO2025027052A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
IL166632A (en) Antibody that binds an alpha-fetoprotein antigen and fusion protein comprising such
EP3758737A4 (en) ANTI-IL-6 ANTIBODIES AND RELATED FUSION CONSTRUCTS AND CONJUGATES
IL304190A (en) Anti-pd-l1 antibodies and fusion proteins thereof
IL306074A (en) Upar antibodies and fusion proteins with the same
EP4417627A4 (en) Recombinant fusion antibody, and antibody-drug conjugate and use thereof
EP3988576A4 (en) Monoclonal antibody-cytokine fusion protein dimer and application thereof
IL299238A (en) Anti-pd-1 antibodies and fusion proteins
IL310778A (en) Sirp-alpha antibodies and conjugates
IL326224A (en) Antibody conjugates and fusion proteins
EP4126965A4 (en) Anti-pd-l1 antibodies and anti-pd-l1/il10 fusion proteins
IL319054A (en) Anti-monomethyl auristatin antibodies and antibody fragments
CA3262971A1 (en) Novel anti-nectin-4 antibodies and antibody-drug conjugates
CA3300270A1 (en) Antibody conjugates and fusion proteins
IL319963A (en) Antibodies, antibody-drug conjugates, preparations and uses thereof
EP4423260A4 (en) Truncated and fusion proteins
IL313553A (en) Fusion proteins comprising alpha-l-iduronidase enzymes and methods
EP4410841A4 (en) ANTI-IL23 ANTIBODY FUSION PROTEIN AND USES THEREOF
HK40110416A (en) Anti-il23 antibody fusion protein and uses thereof
HK40105570A (en) Antibody fusion proteins targeting il-6 receptor and angiogenic factors
EP4107190A4 (en) Fusion proteins and uses thereof
HK40104211A (en) GPC3-TARGETED ANTIBODY INTERFERON α FUSION PROTEIN AND USE THEREOF
IL326476A (en) Anti-cd203c antibody conjugates and uses thereof
HK40104292A (en) Upar antibodies and fusion proteins with the same
IL313159A (en) B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins
IL310247A (en) Nectin-4 antibodies and conjugates